PMID- 37478537
OWN - NLM
STAT- MEDLINE
DCOM- 20231106
LR  - 20231106
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 44
IP  - 6
DP  - 2023 Nov-Dec
TI  - Clinical efficacy in one-year treatment with Artemisia annua-SLIT drops in 
      monosensitized and polysensitized individuals.
PG  - 104002
LID - S0196-0709(23)00216-8 [pii]
LID - 10.1016/j.amjoto.2023.104002 [doi]
AB  - PURPOSE: Seasonal allergic rhinoconjunctivitis (SARC) caused by Artemisia 
      seriously affects patients' quality of life in northern China. This study aimed 
      to estimate further the efficacy and safety of a one-year course of Artemisia 
      annua-sublingual immunotherapy (SLIT) on SARC patients. MATERIALS AND METHODS: 
      This was an open-label, randomized, controlled, single-centre study involving 150 
      SARC patients induced by Artemisia, randomized to SLIT group (n = 75, SLIT along 
      with pharmacotherapy) or control group (n = 75, pharmacotherapy only). According 
      to the skin prick test (SPT) results, the SLIT group was divided into 
      monosensitized and polysensitized groups to analyze the influence of 
      sensitization status on the efficacy of Artemisia annua-SLIT. The clinical 
      indicators of this study were total rhinoconjunctivitis symptom score (TRSS), 
      total medication score (TMS), combined scores of medication and 
      rhinoconjunctivitis symptom (CSMRS), and score of visual analog scale (VAS). 
      Safety was evaluated by the occurrence of adverse events (AEs). Daily 
      administration of the drops was recorded in diaries by the patients. RESULTS: 
      After nearly one year of treatment and follow-ups, there was a significant 
      decline in TRSS, TMS, CSMRS, and VAS from the baseline scores in the SLIT group 
      (p < 0.001). However, as pollen counts increased in 2022, indicators above in the 
      control group increased significantly during the peak pollen phase (PPP) in 2022 
      grass pollen season (GPS) compared to the baseline. Meanwhile, we found no 
      significant difference in TRSS, TMS, CSMRS, and VAS between the monosensitized 
      and polysensitized groups (p > 0.05). Moreover, the result indicated that the 
      clinical improvement in TRSS, TMS, CSMRS, and VAS was still observed in 
      polysensitized patients who were allergic to Artemisia pollen and sensitized to 
      house dust mite (HDM) (n = 15) in PPP of 2022, compared to the baseline value 
      (p < 0.001). CONCLUSION: Artemisia annua-SLIT was proven effective, tolerable and 
      safe in patients with SARC after nearly one year of treatment, whether 
      monosensitization or polysensitization.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Shen, Zhen
AU  - Shen Z
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Zhang, Pengfei
AU  - Zhang P
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Kang, Wei
AU  - Kang W
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Li, Huajing
AU  - Li H
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Shao, Yuan
AU  - Shao Y
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Liu, Lifeng
AU  - Liu L
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Quan, Fang
AU  - Quan F
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Electronic address: 
      quanfang2013@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230715
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
SB  - IM
MH  - Humans
MH  - *Artemisia annua
MH  - Quality of Life
MH  - *Rhinitis, Allergic/therapy
MH  - *Sublingual Immunotherapy/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Artemisia annua
OT  - Monosensitization
OT  - Polysensitization
OT  - Seasonal allergic rhinoconjunctivitis
OT  - Sublingual immunotherapy
COIS- Declaration of competing interest All authors declare no financial or commercial 
      conflicts of interest.
EDAT- 2023/07/22 10:42
MHDA- 2023/07/22 10:43
CRDT- 2023/07/21 18:01
PHST- 2023/06/15 00:00 [received]
PHST- 2023/07/10 00:00 [accepted]
PHST- 2023/07/22 10:43 [medline]
PHST- 2023/07/22 10:42 [pubmed]
PHST- 2023/07/21 18:01 [entrez]
AID - S0196-0709(23)00216-8 [pii]
AID - 10.1016/j.amjoto.2023.104002 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2023 Nov-Dec;44(6):104002. doi: 10.1016/j.amjoto.2023.104002. 
      Epub 2023 Jul 15.